: Myoepithelioma is a rare neoplasm of the salivary glands and accounts for less than 1% of salivary gland neoplasms. Only 7 cases of myoepithelioma in the nasal cavity have been reported till date in literature. : A 61 year old male presented to us with epistaxis. There was a pinkish fleshy mass occupying the right nasal cavity. Biopsy showed evidence of an epithelial tumor of intermediate aggressiveness. We did an endoscopic complete excision of nasal cavity mass. Histopathological examination of the resected tumor was consistent with myoepithelioma. Due to its rarity, the nature of the tumor is not known and regular follow-ups are needed for early detection of recurrence and malignancy. There has been no evidence of tumor recurrence in the 18 months following surgery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645747 | PMC |
http://dx.doi.org/10.1007/s12070-023-03852-9 | DOI Listing |
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
January 2025
To explore the hypothesis of "pathogen storage pool" by analyzing the local microbial community of adenoids. Under the guidance of a 70° nasal endoscope, sterile swabs were used to collect secretions from the adenoid crypts of the subjects. The samples were sent to the laboratory for DNA extraction and standard bacterial 16S full-length sequencing analysis.
View Article and Find Full Text PDFAm J Otolaryngol
December 2024
Department of Pediatrics, Virginia Commonwealth University School of Medicine, 1000 East Broad St., Richmond, VA, USA. Electronic address:
Background: Allergic rhinitis (AR) and acute non-allergic rhinosinusitis (ARS) often present with similar symptoms. While these are generally differentiated by history and occasionally by secretion cell counts, there are few data temporally comparing these conditions.
Methods: A prospective, observational study was conducted to assess nasal mucus properties, nasal obstruction, nasal secretion cells, and health related QOL during the acute phase (Day 5) and during a later phase of illness (Day 14/28).
Acad Radiol
December 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China (Y.W., P.Y., J.W., Z.Z., G.W., Y.Z., Y.Y., Y.M., X.S.); Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Yantai, China (Y.W., P.Y., J.W., Z.Z., G.W., Y.Z., Y.Y., Y.M., X.S.); Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Yantai, China (Y.W., P.Y., J.W., Y.Z., Y.Y., Y.M., X.S.). Electronic address:
Rationale And Objectives: Nasal polyps (NP) and inverted papilloma (IP) are benign tumors within the nasal cavity, each necessitating distinct treatment approaches. Herein, we investigate the utility of a deep learning (DL) model for distinguishing between NP and IP.
Materials And Methods: A total of 1791 patients with nasal benign tumors from two hospitals were retrospectively enrolled.
J Control Release
December 2024
Department of Chemical Engineering, McMaster University, 1280 Main Street, West Hamilton, ON L8S 4L8, Canada. Electronic address:
While bipolar disorder patients can benefit from lithium therapy, high levels of lithium in the serum can induce undesirable systemic side effects. Intranasal (IN) lithium delivery offers a potential solution to this challenge given its potential to facilitate improved lithium transport to brain when delivered to the olfactory mucosa. Herein, a sprayable, in situ forming nanoparticle network hydrogel (NNH) based on Schiff base interactions between chelator-functionalized oxidized starch nanoparticles (SNPs) and carboxymethyl chitosan (CMCh) is reported that can be deployed within the nasal cavity to release ultra-small penetrative SNPs over time.
View Article and Find Full Text PDFVestn Otorinolaringol
December 2024
St. Petersburg Research Institute of Ear, Throat, Nose and Speech, St. Petersburg, Russia.
Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!